Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The countries of mainland South-East Asia, Myanmar, Thailand, Laos, Cambodia and Viet Nam, share a long history of interactions and many cultural similarities, as well as geographical contiguity. They therefore can be usefully examined as a group when considering measures for control of cancer and other non-communicable diseases. Liver cancer is consistently found at higher incidence than most other parts of Asia, with lung cancer as the other most important neoplasm in males. In females cervical and breast cancer about equally predominate, throughout. However, there are also major differences, particularly with regard to stomach and nasopharyngeal cancer, only found at relatively high incidence in Viet Nam. The present review was conducted to gather together registry data on cancer prevalence and epidemiological findings cited in PubMed in order to obtain as comprehensive picture as possible of the present status. It is hoped that future cooperation across the region will facilitate development of coordinated cancer control programs to reduce the burden.
Asian Pac J Cancer Prev 2010
PMID:Cancer epidemiology in mainland South-East Asia - past, present and future. 2055 69

In this paper, we describe the methodology of the case and control selection for the first-wave nested case-control study within the JACC Study. Among the subjects participating in the cohort, serum samples of 42,249 subjects (including 39,242 subjects aged between 40 and 79 at the baseline) were suitable for biochemical analysis. We here selected those who had died by 1997 or who were diagnosed with cancer with sera until 1994 as cases. For each case, 3 to 4 controls with sera were randomly selected, with matching for gender, age (as near as possible) and residential area. As a result, 3,144 cases and 10,661 controls (2,867 cases and 10,351 controls were 40 to 79 years old at the baseline) were selected to measure serum IGF-I, IGF-II, IGFBP-3, TGF-b1 and sFas values and total SOD activity. Cases were older and more likely to be men than the JACC Study subjects. Moreover, they were much older than controls because of the age-dependence of susceptibility to death, especially among men. There were more smokers among cases compared with controls, though drinkers at the baseline were fewer. Among deceased cases, cancer was the leading cause of death, followed by cardiovascular diseases. Lung cancer was most frequent among deceased cancer cases and the next most common site was the stomach. The leading cause of cancer incidence was stomach cancer followed by lung cancer. Simple comparison of means and distribution of IGF-I, IGF-II, IGFBP-3, TGF-b1, sFas and total SOD activity between cases and controls revealed total SOD activity and sFas levels of cases to be higher than controls, while for the other components the opposite was found.
Asian Pac J Cancer Prev 2009 Dec
PMID:Selection of cases and controls for the nested case-control study within the Japan Collaborative Cohort Study: the First-wave. 2055 75

The expression of superoxide dismutases (SODs) has been shown to differ between lung tumor and tumor-free tissues. In the present study, we investigated the association between serum SOD activity and the risk of lung cancer mortality, based on a nested case-control design study within the Japan Collaborative Cohort Study, with a sample of 193 lung cancer patients and 573 matched controls. Blood samples were obtained at the baseline and stored at -80 degrees C until analysis for SOD levels. Serum levels of SODs were divided into quartiles, with the first quartile used as the reference. A conditional logistic model was used to estimate odds ratios (ORs) for lung cancer mortality associated with serum SOD quartile levels. The adjusted ORs and 95% CIs for the second, third; and fourth SOD quartiles were 0.80 (95%CI: 0.49-1.29), 1.32 (0.78-2.25), and 1.07 (0.60-1.89), respectively. In analyses stratified by observation period, the adjusted ORs of the respective quartiles were 0.56 (95%CI: 0.30-1.07), 1.16 ( 0.57-2.37), and 1.11 (0.52-2.35) for the period from the baseline to 1994; and the adjusted ORs of 1.36 (95%CI: 0.65-2.85), 1.71 (0.75-3.87), and 1.06 (0.44-2.53) for the period after 1994. To conclude, we found no significant association between serum SOD level and the risk of deaths from lung cancer in the present study.
Asian Pac J Cancer Prev 2009 Dec
PMID:Relationship between serum levels of superoxide dismutase activity and subsequent risk of lung cancer mortality: Findings from a nested case-control study within the Japan Collaborative Cohort Study. 2055 86

The global burden of cancer is rising with almost 70% of cancer cases being in low- and middle-income countries (LMICs).The Middle East and Asia have two thirds of the world's population and the largest regional concentration of LMICs. Because of massive demographic and epidemiologic transitions, cancer mortality is projected to increase substantially in these populations. Lung cancer among men and breast cancer among women are the most prominent cancer sites in both the Middle East and Asia. Enhanced tobacco control and managing obesity are the most important measures for effective control of most cancers. However, detailed research is required within each population to best identify risk factors and to develop evidence-based methods for cancer prevention. International collaborations are an essential step in facilitating this process, because it can improve cancer registries, create robust infrastructure, improve skills of personnel and lead to effective cancer control and prevention.
Asia Pac J Public Health 2010 Jul
PMID:Cancer in the global health era: opportunities for the Middle East and Asia. 2056 37

Lung cancer is one of the most common cancers in the world, and the incidence of lung cancer is increasing. Risk analysis of environmental chemicals on lung carcinogenesis is particularly important. Detection of chemopreventive agents of lung carcinogenesis is also important to reduce our risk of lung cancer. For that purpose, it is necessary to establish reliable in vivo animal models of lung carcinogenesis. The A/J mouse is a mouse strain sensitive to lung carcinogens, and also develops spontaneous lung tumors without any chemical treatment. We have demonstrated that a treatment of 4-(methylnitrosamino)-1-(3-pyridyle)-1-butanone (NNK), a tobacco specific nitrosamine, or 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (MeIQx), a heterocyclic amine, induced lung tumors in the female A/J mouse in 16 and 32 weeks. The lung tumors developed in the A/J mouse are histopathologically classified as adenocarcinomas, adenomas, and alveolar cell hyperplasias. Some of these types of lung cancer are similar to those of human lung cancer. We also investigated the chemopreventive effects of bovine LF (bLF) on different phases of NNK-induced lung tumorigenesis in A/J mice. The A/J mouse is very useful mouse strain as a reliable in vivo model, which can be used for risk analysis of lung carcinogenesis.
Asian Pac J Cancer Prev 2010
PMID:Risk analysis of environmental chemicals on lung carcinogenesis. 2059 18

Although bone marrow micrometastasis may remain silent, its detection changes the staging and management of lung cancer. In the present study conducted in West Bengal, India, 74 diagnosed bronchogenic carcinoma cases (28 squamous cell carcinomas, 20 adenocarcinomas, 9 small cell carcinomas, 4 large cell carcinomas, 13 unclassified) in early stages (stage I, II and IIIA) were included. Complete hemograms, bone marrow aspiration and cell blocks of aspirated material, trephine biopsy were done for detection of micrometastasis. Overall micrometastases in bone marrow were noted in 17 cases (23.0%). We detected marrow metastasis in 44.4% cases of small cell carcinomas and 21.2% cases of non small cell lung cancer (50% of large cell carcinomas, 20% of adenocarcinomas, 17.9% of squamous cell carcinomas) and 15.4% cases of unclassified carcinoma. We found a statistically significant correlation between marrow metastasis and low platelet count (P=0.0001) and high ESR (P=0.0003), but no significant correlation with hemoglobin percentage (P=0.36), total leukocyte count (P=0.58) and eosinophil count (P=0.44). A definite correlation noted between micrometastasis with the clinical stage (no case in Stage I, 12.5% in Stage II, 30.4% in Stage IIIA patients). We emphasize that detection of micrometastasis is essential particularly in non small cell cancers, where treatment with curative intent is planned, which can be suitably done by morphological study of bone marrow aspirate and biopsy in countries like India.
Asian Pac J Cancer Prev 2010
PMID:Occult micrometastasis to bone marrow in early lung cancer: a clinicopathologic study from West Bengal, India. 2103 47

The diagnosis and treatment of cancers, which rank among the leading causes of mortality in developed nations, presents substantial clinical challenges. The genetic and epigenetic heterogeneity of tumors can lead to differential response to therapy and gross disparities in patient outcomes, even for tumors originating from similar tissues. High-throughput DNA sequencing technologies hold promise to improve the diagnosis and treatment of cancers through efficient and economical profiling of complete tumor genomes, paving the way for approaches to personalized oncology that consider the unique genetic composition of the patient's tumor. Here we present a novel method to leverage the information provided by cancer genome sequencing to match an individual tumor genome with commercial cell lines, which might be leveraged as clinical surrogates to inform prognosis or therapeutic strategy. We evaluate the method using a published lung cancer genome and genetic profiles of commercial cancer cell lines. The results support the general plausibility of this matching approach, thereby offering a first step in translational bioinformatics approaches to personalized oncology using established cancer cell lines.
Pac Symp Biocomput 2011
PMID:Matching cancer genomes to established cell lines for personalized oncology. 2112 Oct 52

The aim of this study is to compare cancer survivals of Indigenous and non-Indigenous Australians and consider health-service and research implications Cancer registry data from South Australia were used to calculate disease-specific survivals for Indigenous (n=671) and sampled non-Indigenous (n=15,799) patients diagnosed during 1977-2007, using Kaplan-Meier estimates and Cox proportional hazards regression. Indigenous and non-Indigenous five-year survivals were respectively: 40% and 57% for all cancer sites combined; 61% and 80% for female breast; 34% and 56% for colon/rectum; and 63% and 73% for cervix; whereas one-year survivals for cancers of unknown primary site were 5% and 22% respectively. Conversely, although not statistically significant (p=0.262), lung cancer survival tended to be higher in Indigenous than non-Indigenous patients. For all sites combined, Indigenous patients had lower survivals up to 70-79 years. The relative risk of death in Indigenous compared with non-Indigenous patients was 2.0 after adjusting for socio-demographic factors and diagnostic period, reducing to 1.4 when also adjusting for prognosis by primary site. Relative risks were 3.7 and 2.7 respectively for Indigenous compared with non-Indigenous patients from Far North remote communities. We conclude that relative risks for Indigenous compared with non-Indigenous patients for all cancers combined are elevated, as seen in the Northern Territory and Queensland. Despite uncertain accuracy of recording of Indigenous status, independent studies show risk elevations and point to the need to prevent cancers, particularly those of high lethal potential, to detect cancers earlier, and to complete planned treatment. A concerted health-service response is needed to address contributing geographic, socio-economic and cultural factors.
Asian Pac J Cancer Prev 2010
PMID:Exploring differences in survival from cancer among Indigenous and non-Indigenous Australians: implications for health service delivery and research. 2113 7

In cancer metastasis, secreted proteins play an important role in promoting cancer cell migration and invasion and thus also in the increase of cancer metastasis in the extracellular microenvironment. In this study, we developed a strategy that combined a simple gel-aided protein purification with iTRAQ labeling to quantify and discover the metastasis-associated proteins in the lung cancer cell secretome. Secreted proteins associated with lung cancer metastasis were produced using CL1-0 and CL1-5 cells with different metastatic abilities. Quantitative secretomics analysis identified a total of 353 proteins, 7 of which were considered to be metastasis-associated proteins. These included TIMP1, COL6A1, uPA, and AAT, all of which were higher in CL1-5, and AL1A1, PRDX1, and NID1, which were higher in CL1-0. Six of these metastasis-associated proteins were validated with Western blot analysis. In addition, pathway analysis was performed in building the interaction network between the identified metastasis-associated proteins. Further functional analysis of COL6A1 on the metastatic abilities of CL1 cells was also carried out. An RNA interference-based knock-down of COL6A1 suppressed the metastatic ability of CL1-5 cells; in contrast, a plasmid-transfected overexpression of COL6A1 increased the metastatic ability of CL1-0 cells. This study describes a simple and high throughput sample purification method that can be used for the quantitative secretomics analysis of metastasis-associated proteins.
 ...
PMID:Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. 2118 46

DNA repair enzymes play an important role in the development of various kinds of cancer. We here analyzed associations of XPD Lys751Gln, APEX1 Asp148Glu, XRCC1 Arg399Gln, and XRCC3 Thr241Met gene polymorphisms in DNA repair pathways in relation to the risk of lung cancer using PCR-RFLP. The study involved 104 lung cancer patients and 120 non-cancer controls divided into non-smokers and smokers. We found a statistically significant interaction between APEX1 Asp148Glu and the risk for lung cancer (adjusted OR 2.78, 95% CI 1.58-4.90, p=0.0004), of both adenocarcinoma (adjusted OR 2.24, 95%CI 1.18-4.25, p=0.014) and squamous cell carcinoma (adjusted OR 4.75, 95%CI 1.79-12.6, p=0.002) types. XRCC1 Arg399Gln showed a borderline significant association with adenocarcinoma (adjusted OR 1.89, 95%CI 1.00-3.57, p=0.051). The combined effect of smoking and presence of the APEX1 Asp148Glu demonstrated a significant association with risk of lung cancer (adjusted OR 3.61, 95% CI 1.74-7.50, p=0.001). The XPD Lys751Gln and XRCC3 Thr241Met genotypes displayed no statistically significant risk. Our findings suggest that the APEX1 Asp148Glu is associated with increased risk for primary lung cancer in Japanese individuals partaking in smoking.
Asian Pac J Cancer Prev 2010
PMID:APEX1 Asp148Glu gene polymorphism is a risk factor for lung cancer in relation to smoking in Japanese. 2119 60


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>